Browse Category

NASDAQ:ATRO News 8 January 2026 - 9 January 2026

Astronics (ATRO) stock rises again after Q4 revenue update and 2026 sales forecast

Astronics (ATRO) stock rises again after Q4 revenue update and 2026 sales forecast

Astronics shares rose 1.7% to $65.88 Friday morning after the company reported unaudited fourth-quarter revenue of $236–$239 million, up 14% year-over-year. Bookings reached $257 million for the quarter, with 2025 orders at $924 million. Management projected 2026 revenue between $950 million and $990 million. The stock surpassed analysts’ average 12-month target price of $60.75.
Astronics stock jumps as ATRO beats Q4 revenue target, rolls out 2026 sales outlook

Astronics stock jumps as ATRO beats Q4 revenue target, rolls out 2026 sales outlook

Astronics shares jumped 8.5% to $63.20 after the company reported preliminary fourth-quarter revenue of $236 million to $239 million, above its prior forecast. The aerospace supplier set 2026 revenue guidance at $950 million to $990 million. Preliminary bookings for the quarter reached about $257 million. Investors await more detail on margins and cash flow next week.

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop